| Not Yet Recruiting | Long-term Study to Evaluate Safety and Persistence of GF-CART01 NCT06985576 | GenomeFrontier Therapeutics TW Co., Ltd. | — |
| Not Yet Recruiting | Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy NCT07463781 | Fondazione Italiana Linfomi - ETS | — |
| Not Yet Recruiting | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma NCT07502872 | Brown University | Phase 2 |
| Not Yet Recruiting | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/ NCT07225439 | Paolo Caimi, MD | Phase 1 |
| Recruiting | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579 | Vironexis Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large NCT06588205 | Fondazione Italiana Linfomi - ETS | — |
| Recruiting | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma NCT06765317 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies NCT06208735 | British Columbia Cancer Agency | Phase 1 |
| Recruiting | A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma NCT06736613 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL NCT06693830 | Hua-Jay J Cherng, MD | N/A |
| Recruiting | SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265 | Verismo Therapeutics | Phase 1 |
| Recruiting | Epcoritamab-CAR T Cells for Large B-cell Lymphomas NCT06458439 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Recruiting | Emapalumab Prevention of CAR-T Cell Associated Toxicities NCT06550141 | Marcela V. Maus, M.D.,Ph.D. | Phase 2 |
| Recruiting | Immunotherapy in Lymphoma NCT06796517 | Sung-Soo Park | — |
| Recruiting | Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High NCT06249191 | OHSU Knight Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) NCT06343311 | Estrella Biopharma, Inc. | Phase 1 / Phase 2 |
| Recruiting | Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Trea NCT06015880 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies NCT06014762 | Poseida Therapeutics, Inc. | Phase 1 |
| Completed | Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) NCT06004167 | Massachusetts General Hospital | N/A |
| Recruiting | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients NCT06287398 | Australasian Leukaemia and Lymphoma Group | Phase 2 |
| Active Not Recruiting | Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL NCT06093841 | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 2 |
| Recruiting | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Recruiting | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment NCT05890352 | SWOG Cancer Research Network | Phase 2 |
| Not Yet Recruiting | Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomar NCT05834426 | Sociedad de Lucha Contra el Cáncer del Ecuador | — |
| Recruiting | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or NCT05660395 | ADC Therapeutics S.A. | Phase 1 |
| Recruiting | Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019 | Schrödinger, Inc. | Phase 1 |
| Active Not Recruiting | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma NCT05621096 | University of Nebraska | Phase 1 |
| Active Not Recruiting | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma NCT05757700 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Lar NCT05455697 | University of Washington | Phase 1 / Phase 2 |
| Recruiting | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma NCT05256641 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Recruiting | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies NCT05653271 | Acepodia Biotech, Inc. | Phase 1 |
| Active Not Recruiting | Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Agg NCT05464329 | Washington University School of Medicine | Phase 1 |
| Recruiting | Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma NCT05412290 | Washington University School of Medicine | Phase 1 |
| Active Not Recruiting | Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma NCT05263583 | Cothera Bioscience, Inc | Phase 2 |
| Terminated | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell NCT04933617 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher NCT04914741 | Peter MacCallum Cancer Centre, Australia | Phase 1 / Phase 2 |
| Suspended | Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL NCT04855253 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Unknown | Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL NCT04796857 | Huiqiang Huang | Phase 1 / Phase 2 |
| Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients NCT04858568 | University Hospital Southampton NHS Foundation Trust | — |
| Terminated | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies NCT04844086 | Eden BioCell Ltd. | Phase 1 |
| Recruiting | A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma NCT04594642 | AstraZeneca | Phase 1 |
| Recruiting | Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients NCT04836507 | Curocell Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma NCT04257578 | University of Washington | Phase 1 / Phase 2 |
| Withdrawn | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity NCT04503538 | Wake Forest University Health Sciences | N/A |
| Completed | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL NCT04555811 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Unknown | DLBCL Interim Response Evaluation for Customised Therapy NCT04226937 | Cambridge University Hospitals NHS Foundation Trust | — |
| Active Not Recruiting | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma NCT04479267 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Active Not Recruiting | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell NCT04542824 | Genmab | Phase 1 / Phase 2 |
| Unknown | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL NCT04476459 | Huiqiang Huang | Phase 1 / Phase 2 |
| Unknown | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma NCT04058470 | Huiqiang Huang | Phase 1 / Phase 2 |
| Terminated | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas NCT04358458 | Genmab | Phase 1 / Phase 2 |
| Recruiting | Study of CAR-T Therapy in Older Patients NCT04300998 | Memorial Sloan Kettering Cancer Center | — |
| Terminated | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients Wit NCT04205838 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma NCT03995147 | University of Chicago | Phase 2 |
| Unknown | DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma NCT03837873 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Active Not Recruiting | Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large NCT03656835 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged H NCT03620578 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 2 |
| Completed | Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell NCT04067414 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Completed | A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax NCT03255096 | Hoffmann-La Roche | Phase 1 |
| Terminated | Cyclophosphamide and Alemtuzumab In Lymphoma NCT03132584 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas NCT03036904 | Weill Medical College of Cornell University | Phase 1 |
| Withdrawn | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Ly NCT02623920 | University of Arizona | Phase 2 |
| Completed | Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Ad NCT01809600 | Gachon University Gil Medical Center | — |
| Completed | Treatment for Advanced B-Cell Lymphoma NCT01859819 | New York Medical College | Phase 2 |